Simulations Plus, Inc. Income Statement – GETTEX:SD3
This article presents the income statement for Simulations Plus, Inc. (SD3) listed on GETTEX, highlighting key financial figures. For Q1 2026, the company reported a total revenue of €15.88 million, marking a 6.28% increase from the previous quarter, and a net income of €582.89 thousand. The financial data is shown in both annual and quarterly formats, detailing income and expenses over several periods.
Discipline and Rules-Based Execution in SLP Response
This article provides an AI-driven stock analysis for Simulations Plus Inc. (NYSE: SLP), recommending a short bias due to weak sentiment across all time horizons. It details several trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis highlights an exceptional 133.5:1 risk-reward short setup.
Simulations Plus AGM: Shareholders Approve All Proposals, Back Annual Say-on-Pay Votes
Simulations Plus shareholders approved all proposals at their annual meeting, including the election of four directors, ratification of Rose, Snyder & Jacobs LLP as auditor, and an amendment to the 2021 Equity Incentive Plan. Shareholders also voted for an annual say-on-pay frequency, overriding the board's recommendation for a three-year cadence, although this vote is non-binding. The company expects to file final voting results within four business days.
Herald Investment Management Ltd Makes New $3.02 Million Investment in Simulations Plus, Inc. $SLP
Herald Investment Management Ltd has made a new investment of $3.02 million in Simulations Plus, Inc. (NASDAQ:SLP), acquiring 200,000 shares, representing approximately 0.99% of the company. Despite this new stake and a recent stock opening at $12.29, Simulations Plus has faced analyst downgrades and missed its quarterly EPS estimate, reporting $0.13 versus an $0.18 estimate, alongside a negative net margin of -81.66%. The company currently holds a consensus "Hold" rating from analysts with a target price of $25.00.
Simulations Plus hosts AI event at ASCPT to explore practical tools
Simulations Plus will host an event at ASCPT on Thursday, March 5th, focusing on the practical applications of AI in Model-Informed Drug Development (MIDD). Titled "From Debate to Deployment: Responsible, Practical AI in MIDD," the Lunch and Learn session will explore how AI tools can be effectively utilized in drug development. Attendees are encouraged to arrive early due to limited seating.
ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. This investigation comes after a significant stock drop on July 15, 2025, when Simulations Plus reported sales figures that missed consensus estimates. Investors who purchased SLP securities are encouraged to contact the firm to join a prospective class action.
Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of "Hold" by Brokerages
Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus "Hold" recommendation from ten brokerages, with an average 12-month price target of $25.00. The company reported Q4 EPS of $0.13, missing estimates, but revenue beat expectations at $18.42 million. Institutional investors hold approximately 78.08% of the shares, with notable increases from firms like Tributary Capital and North Star.
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Simulations Plus, Inc. has announced the extension of two research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). These collaborations will support ongoing research into computational approaches and new approach methodologies (NAMs) for assessing food and chemical safety. The extended projects align with regulatory guidance encouraging non-animal based research, including AI-driven and in silico methods, to modernize safety evaluations.
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Simulations Plus, Inc. has announced the extension of two research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). These collaborations focus on advancing computational approaches and new approach methodologies (NAMs) for food and chemical safety assessments, aligning with federal initiatives to use non-animal based research. The extensions highlight the continued federal interest in evaluating AI-based approaches, an area where Simulations Plus has significant expertise.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations of misleading business information. This investigation stems from a Benzinga article reporting that Simulations Plus' third-quarter 2025 earnings and sales fell short of expectations, leading to a significant 25.75% stock drop on July 15, 2025. Investors who purchased Simulations Plus securities are encouraged to contact the firm to inquire about joining a prospective class action lawsuit.
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 26% Pounding
Simulations Plus, Inc. (NASDAQ:SLP) recently experienced a significant 26% drop in its share price over the last month, contributing to a 60% decline over the past year. Despite a high price-to-sales (P/S) ratio of 3.7x compared to an industry average of 2.2x, the company's revenue growth has been slower than its peers. Analysts forecast an 8.5% annual revenue growth for Simulations Plus over the next three years, lower than the industry's 13% average, suggesting its elevated P/S ratio may not be justified by future prospects.
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. (NASDAQ:SLP) has seen its share price drop by 26% in the last month, contributing to a 60% loss over the past 12 months. The company's price-to-sales (P/S) ratio of 3.7x is high compared to the industry average, and its forecasted revenue growth of 8.5% per year over the next three years is less attractive than the industry's 13% forecast. This suggests that despite the recent plunge, the stock may still be overvalued if its P/S ratio adjusts to align with its growth outlook.
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Simulations Plus, Inc. (NASDAQ:SLP) is estimated to be 38% undervalued based on its current share price of US$14.14, with a fair value estimate of US$22.72 using a two-stage Discounted Cash Flow (DCF) model. The analysis projects future cash flows over ten years, followed by a terminal value calculation, resulting in a total equity value of US$458 million. While the DCF model suggests a significant discount, the article emphasizes that it should be used as a guide alongside other financial health and future earnings considerations.
Simulations Plus (NASDAQ:SLP) Cut to Hold at Zacks Research
Zacks Research has downgraded Simulations Plus (NASDAQ:SLP) from a "strong-buy" to a "hold" rating, contributing to the stock's consensus "Hold" rating and a target price of $25.00. The company recently missed EPS expectations, reporting $0.13 against an anticipated $0.18, though revenue slightly exceeded forecasts at $18.42 million. Simulations Plus also exhibits a negative net margin of 81.66%, and its stock reflects these challenges, opening down 8.2% at $15.40.
Simulations Plus to Participate in Upcoming Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will participate in three upcoming investor conferences in February and March 2026. These include the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, the TD Cowen 46th Annual Health Care Conference, and the KeyBanc Healthcare Forum. The CEO will engage in one-on-one meetings and fireside chats at these events.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities class action claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information to investors. This investigation stems from a significant stock drop on July 15, 2025, after the company's third-quarter earnings missed analyst expectations. Investors who purchased Simulations Plus securities are encouraged to contact the Rosen Law Firm for information on joining the prospective class action to potentially recover losses.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities class action claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. This investigation comes after Simulations Plus' stock significantly dropped on July 15, 2025, due to lower-than-expected third-quarter sales reported by Benzinga. Investors who purchased Simulations Plus securities are encouraged to contact the law firm to learn about their potential compensation rights in the prospective class action.
Simulations Plus to Participate in Upcoming Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will participate in three upcoming investor conferences in February and March 2026. These include the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, the TD Cowen 46th Annual Health Care Conference, and the KeyBanc Healthcare Forum. O'Connor will engage in one-on-one meetings and fireside chats at these events.
SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) after the company allegedly issued misleading business information. The investigation stems from a significant stock drop in July 2025 following a disappointing third-quarter earnings report. Shareholders who purchased Simulations Plus securities are encouraged to contact the firm regarding joining a potential class action lawsuit.
SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company may have issued materially misleading business information. This investigation stems from a significant stock decline on July 15, 2025, after a Benzinga article reported weaker demand and softened outlook for Simulations Plus, missing analyst consensus for its third-quarter 2025 sales. Investors who suffered losses are encouraged to contact the law firm for potential compensation.
Simulations Plus invites scientists to MIDD Tokyo event
Simulations Plus is hosting the MIDD Tokyo event, a two-day gathering designed to enhance expertise in model-informed drug development. Scientists will gain knowledge and skills in cutting-edge techniques and strategies, offering a valuable opportunity for professionals to advance their capabilities and network with peers. Further details are available via provided links for interested participants.
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. This investigation stems from a significant stock drop on July 15, 2025, after a Benzinga article reported weaker demand and softened outlook, with third-quarter sales falling short of consensus estimates. The firm is preparing a class action lawsuit and encourages affected investors to contact them for potential compensation.
Simulations Plus, Inc. (SLP) Stock Analysis: Potential Upside of 39.28% Amidst Challenging Financial Metrics
Simulations Plus, Inc. (SLP) shows a potential upside of 39.28% according to analysts, despite facing financial challenges like declining revenue, negative EPS, and a negative Return on Equity. The company, which specializes in AI and machine learning for drug discovery, maintains a robust free cash flow and a strategic market position. Investors are advised to monitor financial health closely while considering the stock's growth potential.
SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations of materially misleading business information. This investigation comes after a significant drop in stock price on July 15, 2025, when the company's third-quarter earnings and sales projections fell short of market expectations. The firm encourages affected investors to contact them to join a prospective class action.
Simulations Plus (NASDAQ:SLP) Stock Price Passes Above 200-Day Moving Average - Here's What Happened
Simulations Plus (NASDAQ:SLP) saw its stock price climb above its 200-day moving average on Monday, trading as high as $20.73. Despite missing Q results' EPS consensus and showing a negative net margin, the stock closed at $20.11 on a volume of 240,372 shares. Institutional investors hold a significant portion of the company's stock, and analysts maintain a "Hold" rating with an average target price of $25.00.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company may have issued materially misleading business information. This investigation stems from a significant stock drop on July 15, 2025, after the company's third-quarter 2025 earnings report showed sales falling short of analyst estimates. Investors who purchased SLP securities are encouraged to contact the Rosen Law Firm for information on joining a prospective class action to recover losses.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations of materially misleading business information. This investigation stems from a July 2025 Benzinga article reporting that Simulations Plus's third-quarter 2025 earnings and sales fell short of consensus estimates, causing a significant stock drop. Investors who purchased SLP securities are encouraged to contact the law firm to learn about joining a prospective class action to recover losses.
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
The Rosen Law Firm is investigating potential securities class action claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations of misleading business information. This investigation follows a significant stock drop on July 15, 2025, after the company's third-quarter earnings and sales fell short of analyst expectations. Investors who purchased Simulations Plus securities may be entitled to compensation and are encouraged to contact the firm.
Simulations Plus, Inc. (SLP): Investor Outlook and Analyst Consensus Reveal 18.76% Upside Potential
Simulations Plus, Inc. (SLP), a healthcare sector company specializing in health information services, shows an 18.76% upside potential according to analyst consensus. Despite recent declines in revenue growth and EPS, the company's cutting-edge software using AI and machine learning for drug discovery positions it uniquely in the market. Analyst ratings are cautiously optimistic, with an average target price of $24.67, suggesting an intriguing option for growth-oriented investors.
Bioequivalence Studies Market to Reach US$1.35 Billion by 2033,
The global bioequivalence studies market is projected to reach US$1.35 billion by 2033, growing at a CAGR of 7.5% from 2025. This growth is driven by advancements in PBPK/PBBM modeling, strong regulatory support for model-informed drug development, and the increasing adoption of AI/ML in pharmaceutical R&D. Key players like Simulations Plus and Certara are leading innovation through strategic partnerships and new product launches, while oncology applications and in vivo studies currently dominate the market.
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
Simulations Plus (Nasdaq: SLP) hosted its 2026 Virtual Investor Day, showcasing its integrated, AI-enabled platform for drug development. The company emphasized combining scientific rigor with modern cloud and AI capabilities to address increasing scientific complexity and evolving regulatory expectations. Simulations Plus aims to transform its tools into a unified modeling ecosystem by focusing on grounded intelligence and responsible AI practices, aligning with FDA and EMA guidance.
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
Simulations Plus hosted its 2026 Virtual Investor Day to discuss its advancements in integrated, AI-enabled platforms for drug development. The company emphasized combining scientific expertise with modern cloud and AI capabilities to meet evolving industry needs and regulatory expectations. They highlighted their focus on "grounded intelligence," ensuring AI augments mechanistic modeling for explainable and auditable results aligned with FDA and EMA good AI practice principles.
Johnson Fistel Investigates Simulations Plus for Potential Securities Law Violations
Johnson Fistel, PLLP is investigating potential federal securities law violations by Simulations Plus, Inc. (NASDAQ: SLP) following significant stock drops in June and July 2025. The investigation focuses on alleged misrepresentations and omissions regarding the company's acquisition of Pro-ficiency Holdings, Inc. and issues with internal controls over financial reporting, which led to a $77.2 million charge and the dismissal of its auditor. Investors who suffered losses are encouraged to contact the firm for potential recovery options.
Johnson Fistel Investigates Simulations Plus for Potential Securities Law Violations
Johnson Fistel, PLLP is investigating potential claims against Simulations Plus, Inc. (NASDAQ: SLP) for alleged federal securities law violations. The investigation follows significant stock price drops after the company announced disappointing financial results, internal control issues, and a large charge related to previous acquisitions, including the dismissal of its auditor. Investors who purchased SLP securities are encouraged to contact Johnson Fistel to determine their eligibility for potential class action recovery.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. This investigation stems from a July 2025 report by Benzinga, which stated that Simulations Plus stock fell 25.75% after its third-quarter 2025 earnings and sales figures fell short of consensus estimates. The firm is encouraging investors who purchased SLP securities to inquire about joining a prospective class action.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) following allegations that the company issued materially misleading business information. The investigation stems from a Benzinga article published on July 15, 2025, which reported that Simulations Plus's third-quarter 2025 sales of $20.4 million missed analyst consensus estimates and led to a significant drop in its stock price. Investors who purchased Simulations Plus securities may be entitled to compensation through a class action led by Rosen Law Firm.
Stephens Investment Management Group LLC Buys 124,264 Shares of Simulations Plus, Inc. $SLP
Stephens Investment Management Group LLC significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 46.3% in the third quarter, acquiring 124,264 additional shares. The firm now holds 392,840 shares valued at $5.92 million, representing approximately 1.95% of the company. Despite institutional confidence, Simulations Plus recently missed quarterly EPS expectations but saw revenue modestly beat forecasts, with a current "Hold" consensus rating and a $25 price target.
Simulations Plus, Inc. (NASDAQ:SLP) Given Average Rating of "Hold" by Brokerages
Simulations Plus, Inc. (NASDAQ:SLP) has received an average "Hold" rating from eleven brokerages, with an average 12-month price target of $25.00. The company recently missed quarterly EPS expectations but slightly beat on revenue. Institutional investors hold a significant portion of the shares, with notable purchases by Tributary Capital and North Star.
Simulations Plus (NASDAQ:SLP) shareholders are up 12% this past week, but still in the red over the last five years
Simulations Plus (NASDAQ:SLP) shareholders have seen a 12% increase this past week and a 32% rise in the last quarter, yet the stock remains down 72% over the last five years. The company's share price decline coincided with EPS falling into negative territory, aggravated by recent extraordinary items. While the market has gained 18% over the past year, Simulations Plus investors have faced a 32% loss for the same period.
Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know
Simulations Plus (SLP) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights changes in a company's future earnings potential, which is strongly correlated with stock price movements. This upgrade indicates a positive earnings outlook for Simulations Plus, suggesting potential for its stock price to increase.
Simulations Plus, Inc. SEC 10-Q Report
Simulations Plus, Inc. (SLP) has released its first-quarter fiscal year 2025 Form 10-Q report, detailing a 3% decrease in total revenues to $18.4 million, primarily due to a 17% drop in software-related revenue. Despite this, the company saw a significant improvement in gross profit and net income, largely driven by cost management, operational efficiency, and a 51% increase in R&D expenses. The report also highlights strategic initiatives including a headcount reduction, increased sales and marketing, and a shift to a remote-first operating model.
Simulations Plus: Fiscal Q1 Earnings Snapshot
Simulations Plus Inc. (SLP) reported fiscal first-quarter earnings of $676,000, or 3 cents per share, which adjusted for one-time items, amounted to 13 cents per share. The company, which specializes in software for pharmaceutical research, posted revenues of $18.4 million, exceeding analysts' forecasts. Simulations Plus also provided a full-year earnings outlook ranging from $1.03 to $1.10 per share and revenue between $79 million and $82 million.
Simulations Plus Q1 Earnings Call Highlights
Simulations Plus reported a 3% decrease in Q1 revenue to $18.4 million, with software revenue down 17% and services revenue up 16%, driven by growth in commercialization and medical communication services. The company maintained its full fiscal year 2026 guidance for revenue, adjusted EBITDA margin, and adjusted EPS, emphasizing AI-enabled product upgrades and regulatory tailwinds. They ended the quarter with $35.7 million in cash and no debt, planning an investor day on January 21 to detail their product roadmap.
Simulations Plus Inc (NASDAQ:SLP) Meets Q1 Revenue Target Amid Software Segment Decline
Simulations Plus Inc. (NASDAQ:SLP) reported mixed financial results for Q1 fiscal year 2026, meeting its revenue target of $18.4 million due to strong services growth, despite a 17% decline in its software segment. Adjusted EPS was slightly below consensus at $0.13. The company reaffirmed its full-year 2026 guidance, anticipating a recovery in growth and profitability, particularly in its software division, and investors are looking to the upcoming Virtual Investor Day for more clarity.
Simulations Plus, Inc. (NASDAQ:SLP) Q1 2026 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP) reported Q1 2026 earnings, missing expectations with $0.13 EPS against an estimated $0.18. The company closed fiscal 2025 with strong execution, meeting full-year guidance, and is strategically resetting its operating model to align product, R&D, consulting, and business development. Despite market volatility and challenging client budgets in 2025, Simulations Plus anticipates stabilization in 2026, driven by clearer pharmaceutical pricing frameworks and improved biotech funding, with a focus on integrating AI and cloud computing into its biosimulation solutions.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
Simulations Plus, Inc. reported its first-quarter fiscal 2026 financial results, with total revenue decreasing 3% to $18.4 million due to a 17% decline in software revenue, partially offset by a 16% increase in services revenue. Despite the mixed revenue performance, the company reaffirmed its fiscal year 2026 guidance, citing strong bookings, annual software price increases, and favorable market dynamics. Simulations Plus plans to host a virtual Investor Day on January 21, 2026, to showcase its new product vision and AI solutions in model-informed and AI-accelerated drug development.
Earnings call transcript: Simulations Plus Q1 2026 misses EPS forecast
Simulations Plus Inc. reported its Q1 2026 earnings, missing EPS forecasts with $0.13 against an expected $0.19, a 31.58% negative surprise. However, the company surpassed revenue expectations, reaching $18.4 million compared to the anticipated $17.97 million. Following the report, the stock declined by 4.95% in aftermarket trading, reflecting investor concerns over the EPS miss despite the revenue beat.
Simulations Plus: Overview of First Quarter Financial Results
Simulations Plus Inc. reported its first-quarter financial results, earning $676,000, or 3 cents per share, which rose to 13 cents per share after adjustments. The pharmaceutical research software company generated $18.4 million in revenue, surpassing analyst expectations of $18.1 million. For the full year, the company projects earnings between $1.03 and $1.10 per share and revenue ranging from $79 million to $82 million.
Simulations Plus Posts Mixed Q1 2026 Results, Reaffirms Outlook
Simulations Plus (SLP) reported mixed financial results for Q1 FY2026, with revenue declining by 3% year-over-year to $18.4 million due to a significant drop in software revenue, although services revenue increased by 16%. Despite lower adjusted EBITDA and net income compared to the previous year, the company increased its GAAP net income, improved gross margin to 59%, and reaffirmed its full-year 2026 guidance, citing strong services performance and solid bookings. The stock currently holds a "Hold" rating from analysts with an average price target of $19.00, and TipRanks' AI Analyst Spark rates SLP as "Neutral" due to mixed financial signals but strong balance sheet and cash flow.
Simulations Plus, Inc. Q1 Profit Increases, But Misses Estimates
Simulations Plus, Inc. (SLP) reported increased Q1 profit year-over-year but missed Street estimates. The company's earnings were $0.68 million, or $0.03 per share, which is up from $0.21 million last year but below the expected $0.20 per share. Revenue for the period decreased by 2.6% to $18.42 million.
